.png){kind=icon}
Return
Zaleplon
.png){kind=icon}
PRE
AI
DOI：10.2165/00023210-199911050-00006.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Zaleplon is a nonbenzodiazepine sedative-hypnotic which acts as a selective agonist at the benzodiazepine omega(1) (type 1) receptor. I n comparison with placebo, zaleplon 10mg taken at bedtime has been shown to significantly reduce sleep latency in both polysomnographic and subjective assessments. Zaleplon 5 and 10mg significantly reduced median time to sleep onset compared with placebo after the first and second weeks of a randomised double-blind study in 422 elderly patients with insomnia. Similarly, zaleplon 10 and 20mg significantly reduced subjective sleep latency from that with placebo throughout a 4-week trial in 574 patients with insomnia. There was no evidence of next-day psychomotor impairment with zaleplon 10mg. In contrast, significant impairments were seen with flurazepam 30mg, zolpidem 20mg, triazolam 0.25mg and zopiclone 7.5mg in some comparative trials. The tolerability profile of zaleplon was similar to that of placebo in clinical trials, and use of zaleplon was not associated with rebound insomnia or other withdrawal effects.
Keywords:
INSOMNIA
CL-284,846
PLACEBO
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
7.4
Papers:
2.5K
Citations:
7.0K
Organization
No organization information available
Cited Papers
No cited papers available